Rose's Income Garden portfolio reached an all-time high, with forward yield dipping slightly to 6% as portfolio value increased. Mastercard stands out with a 14.5% dividend raise, attractive valuation (P/E 26.41 vs. 5-year 34.81x), and robust earnings growth, making it a core hold. Bristol Myers Squibb and AbbVie are both considered holds due to disappointing or modest dividend raises and valuations above historical norms.
NORTH CHICAGO, Ill., March 3, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Leerink Partners Global Healthcare Conference on Tuesday, March 10, 2026.
AbbVie says 55% of Crohn's patients reached remission in a late-stage study, boosting Skyrizi's outlook amid market competition.
AbbVie has grown its dividend by more than 330% since it became a public company in 2013. It generates strong free cash flow, which leaves room for more rate hikes in the future.
In the Phase 3 AFFIRM study in adults with moderately to severely active Crohn's disease, risankizumab (SKYRIZI®) achieved superiority for the co-primary and ranked secondary endpoints at week 12 for induction delivered by subcutaneous (SC) injection versus placebo1 These data support strong efficacy of risankizumab in Crohn's disease while providing potential for an induction choice for patients1 The safety profile of risankizumab SC induction was consistent with its known profile in Crohn's disease, with no new safety risks observed1 NORTH CHICAGO, Ill., March 2, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive topline results from the Phase 3, randomized, placebo-controlled, double-blind AFFIRM study evaluating the efficacy and safety of risankizumab (SKYRIZI®) subcutaneous (SC) induction treatment versus placebo in adult patients with moderately to severely active Crohn's disease (CD).1 The AFFIRM study results show significantly greater proportions of patients treated with risankizumab SC induction achieved the co-primary endpoints of Crohn's Disease Activity Index (CDAI) clinical remissiona (55% vs.
Bahl and Gaynor Inc. cut its holdings in shares of AbbVie Inc. (NYSE: ABBV) by 23.5% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,154,256 shares of the company's stock after selling 968,314 shares during the period. AbbVie
High-yield stocks are outperforming, with a clear rotation from growth to value driving strong returns for dividend-focused investors. Safe, high-yielding companies are still trading at discounts. These 3 are in the process of rerating, providing an appealing position to initiate a position.
111 Capital lessened its position in AbbVie Inc. (NYSE: ABBV) by 77.4% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 4,411 shares of the company's stock after selling 15,143 shares during the period. 111 Capital's holdings in AbbVie were worth $1,021,000 at the
Argent Trust Co lowered its stake in AbbVie Inc. (NYSE: ABBV) by 1.5% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 205,045 shares of the company's stock after selling 3,119 shares during the period. AbbVie accounts for about 1.7% of Argent Trust
The ProShares S&P 500 Dividend Aristocrat ETF (NOBL) is up 9.39% YTD in 2026, decisively outperforming SPY's 1.08%. Dividend Aristocrats are regaining momentum after a weak 2025, with 55 outpacing SPY and 39 posting double-digit gains this year already. Dividend growth is lagging, with 2026's average increase currently at 3.22%, below last year's trend and potentially signaling headwinds.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
DNB Asset Management AS lowered its stake in shares of AbbVie Inc. (NYSE: ABBV) by 1.8% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 493,795 shares of the company's stock after selling 9,251 shares during the period. DNB Asset Management AS's holdings in AbbVie
Aster Capital Management DIFC Ltd bought a new position in shares of AbbVie Inc. (NYSE: ABBV) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 8,915 shares of the company's stock, valued at approximately $2,064,000. AbbVie accounts for about 1.0%
Andra AP fonden increased its position in AbbVie Inc. (NYSE: ABBV) by 43.4% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 107,300 shares of the company's stock after purchasing an additional 32,500 shares during the period. Andra
Guru Stock PicksMS Global Franchise Portfolio has made the following transactions:Reduce in MSCI by 17.11%Sold out in FDSAdd in LSE: EXPN by 13.74%New position i
The stock is performing well thanks to AbbVie's still-growing immunology franchise. The company looks able to launch new products through at least 2031.
Stock News Nvidia posts record quarter, upbeat outlook: Nvidia (NVDA) reported Q4 revenue of $68.13B with data center sales at $62.3B (91% of total) and guided
Merck & Co. (MRK) is upgraded to buy, driven by improving dividend cushion ratio (DCR) and robust FQ4 2025 earnings recovery. MRK's dividend safety strengthens, with a projected DCR of 2.57x for 2026, surpassing both its historical average and ABBV's outlook. AbbVie (ABBV) maintains strong results but faces DCR pressure from CAPEX plans, with a projected 2.19x DCR in 2026.
Pre-Market Stock Futures: Futures are trading higher this morning, but what a difference a day makes after a "Meltdown Monday." Stocks rallied on Tuesday, and all major indices closed higher. While not recouping all of the losses from Monday, a strong bounce-back was a welcome sight for investors. A combination of a rebound in technology... Here Are Wednesday's Top Wall Street Analyst Research Calls: AbbVie, Angel Studios, First Solar, IBM, Kroger, Molson Coors, Oracle, Workday, and More.
Empirical Asset Management LLC increased its position in AbbVie Inc. (NYSE: ABBV) by 206.3% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 10,372 shares of the company's stock after acquiring an additional 6,986 shares during the period. Empirical